Guaiacene sesquiterpenoids from Daphne odora and preparation method and application thereof

By isolating and preparing six new guaifene sesquiterpene derivatives from erbera syllium, the lack of erbera syllium chemical components and pharmacological activities in existing literature was solved, and the problem of lack of erbera syllium chemical components and pharmacological activities in existing literature was demonstrated, showing its neuroprotection and choline Good activity in esterase inhibition has the potential to develop prevention and treatment of Alzheimer's disease.

CN116284037BActive Publication Date: 2024-11-15SHENYANG PHARMA UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310255151.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-15
Publication Date
2024-11-15
Estimated Expiration
2043-03-15

AI Technical Summary

Technical Problem

There is a lack of reports on the chemical composition and pharmacological activities of neroli, especially its application in neuroprotection and cholinesterase inhibition.

Method used

Six new guaifene sesquiterpene derivatives were isolated from the erotica syringe and prepared. The combination of high-resolution mass spectrometry and NMR through ethanol extraction, ethyl acetate extraction, silica gel column chromatography and reverse phase high-performance liquid chromatography. and calculation methods determine its structure and examine its neuroprotective and cholinesterase inhibitory activities.

Benefits of technology

The structure of 6 new compounds was identified and demonstrated good neuroprotective activities and cholinesterase inhibitory activities of Compounds 2 and 3, with the prospect of developing drugs for preventing and treating Alzheimer's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116284037B_ABST
    Figure CN116284037B_ABST
Patent Text Reader

Abstract

The invention discloses a novel skeleton guaiacyl sesquiterpenoid in Daphne aurantiaca and a preparation method and application thereof, belonging to the field of medical technology, and specifically relates to 6 novel guaiacyl sesquiterpenoid derivatives extracted and separated from Daphne aurantiaca, a plant of the genus Daphne in the family Thymelaeaceae. These novel compounds have good neuroprotective activity and cholinesterase inhibitory activity. The preparation method of the invention is simple and easy to implement, has good reproducibility and high purity. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and specifically relates to six guaiacyl sesquiterpene derivatives prepared from Daphne odora and applications of the compounds in neuroprotective activity and cholinesterase inhibitory activity. Background Art

[0002] Daphne: Daphne belongs to the Thymelaeaceae family and has more than 90 species, mainly distributed in Asia, Europe and parts of North Africa. Recent studies have found that plants in this genus have rich and diverse secondary metabolites and have good biological activities such as neuroprotection, cholinesterase inhibition, and antibacterial properties.

[0003] Daphne aurantiaca: Daphne aurantiaca is a dwarf shrub of the genus Daphne in the family Thymelaeaceae, mainly distributed in northwest Yunnan and northwest Sichuan in my country. Currently, there are few reports on the chemical components and pharmacological activities of Daphne aurantiaca. So far, there has been no patent or literature report on the compounds and their activities involved in the present invention. Summary of the invention

[0004] The object of the present invention is to provide a hexa-sesquiterpenoid compound and a preparation method thereof.

[0005] The present invention also provides the application of the sesquiterpenoid compound in neuroprotective activity and cholinesterase inhibitory activity.

[0006] The six sesquiterpenoid compounds isolated from Daphne aurantiaca of the genus Daphne in the family Thymelaeaceae of the present invention have the following structures:

[0007]

[0008] The preparation technology scheme of the present invention comprises the following steps:

[0009] The whole plant of dried Daphne odora was extracted with ethanol, and the extracts were combined and concentrated to obtain an extract. The extract was extracted with ethyl acetate and the obtained components were subjected to silica gel column chromatography and gradient eluted with a dichloromethanol system of 1:0-0:1 to collect 10 components Fr.AJ;

[0010] The component Fr.C was gradient eluted using an ethanol-water system of 20:80-100:0 using HP20, ODS column chromatography to obtain 12 components Fr.C1-Fr.C12;

[0011] Compound 1-6 was obtained by silica gel column chromatography with a petroleum ether-ethyl acetate system of 100:1-1:1 as eluent and by preparative reverse phase high performance liquid chromatography using an acetonitrile-water mobile phase to separate Fr.C5, Fr.C6 and Fr.C7.

[0012] The method for preparing the guaiacane sesquiterpene derivatives in orange flower Daphne is characterized in that the orange flower Daphne used is a plant of the genus Daphne in the family Thymelaeaceae [Daphne aurantiaca].

[0013] The method for preparing the guaiacane sesquiterpene derivatives in Daphne odora is characterized in that the whole plant of dried Daphne odora is extracted with 80% industrial ethanol under reflux for 3 times, each time for 2-3 hours.

[0014] The method for preparing the guaiacyl sesquiterpene derivatives in Daphne odora is characterized in that Fr.C5, Fr.C6 and Fr.C7 are separated using an acetonitrile-water mobile phase of 70:30-30:70.

[0015] The obtained compounds were systematically identified and the results are as follows:

[0016] The structures of compounds 1-6 were identified by high-resolution mass spectrometry, one-dimensional NMR, two-dimensional NMR, computed NMR, computed ECD and X-ray single crystal diffraction. The corresponding spectra are shown in Figure 1-10 As shown, 1 HNMR and 13 C NMR data are shown in Tables 1 and 2.

[0017] Daphaulide A (1): yellow oil; -21.6(c0.14,MeOH); HRESIMS(m / z247.13217[M+H] + ,calcd247.13287) to determine the molecular formula is C 15 H 18 O3; by analyzing daphaulide A 1 HNMR, 13 CNMR, HSQC, HMBC spectra, NMR calculations and ECD calculations confirmed the structure of daphaulide A as a new compound.

[0018] Daphaulide B (2): light yellow oil; -23.8(c0.16,MeOH); HRESIMS(m / z271.1296[M+Na] + ,calcd271.1305) to determine the molecular formula is C 15 H 20O3; by analyzing daphaulideB 1 HNMR, 13 CNMR, HSQC, HMBC spectra, NMR calculations and ECD calculations confirmed the structure of daphaulide B as a new compound.

[0019] Daphaulide C (3): light yellow oil; -19.3(c0.10,MeOH); HRESIMS(m / z217.1198[M+Na] + ,calcd217.1204) to determine the molecular formula is C 12 H 18 O2; by analyzing daphaulideC 1 HNMR, 13 CNMR, HSQC, HMBC spectra, NMR calculations and ECD calculations confirmed the structure of daphaulide C as a new compound.

[0020] Daphaulide D (4): yellow oil; -27.1(c0.13,MeOH); HRESIMS(m / z261.10910[M+Na] + ,calcd261.10973) to determine the molecular formula is C 13 H 18 O4; by analyzing daphaulideD 1 HNMR, 13 CNMR, HSQC, HMBC spectra, NMR calculations and ECD calculations confirmed the structure of daphaulide D, which is a new compound.

[0021] Daphaulide E (5): yellow oil; -22.5(c0.13,MeOH); HRESIMS(m / z265.14316[M+H] + ,calcd265.14344) to determine the molecular formula is C 15 H 20 O4; by analyzing daphaulideE 1 HNMR, 13 CNMR, HSQC, HMBC spectra, NMR calculations and ECD calculations confirmed the structure of daphaulide E as a new compound.

[0022] Daphaulide F (6): colorless needle crystals; -34.7 (c 0.18, MeOH); HRESIMS (m / z 271.1296 [M+Na]+, calcd 271.1305) confirmed the molecular formula to be C 15 H 20 O3; by analyzing daphaulideF 1 H NMR, 13 The structure of daphaulide F was confirmed to be a new compound by C NMR, HSQC, HMBC, NMR and ECD calculations.

[0023] The neuroprotective activity and cholinesterase activity of the six new compounds described in the present invention were investigated. Compounds 2 and 3 showed good neuroprotective activity and cholinesterase inhibitory activity. Therefore, the new guaiacyl sesquiterpene derivatives described in the present invention have the prospect of further development of drugs for the prevention and treatment of Alzheimer's disease.

[0024] A pharmaceutical composition comprises the guaiacane sesquiterpene derivative prepared from Daphne odora or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

[0025] The present invention also provides the use of the guaiacane sesquiterpene derivative prepared from Daphne odora or a pharmaceutical composition containing the compound in the preparation of drugs with neuroprotective activity and cholinesterase inhibitory activity.

[0026] The advantages of the present invention are that the compounds are all new compounds with novel structures and are all optically pure compounds with definite stereoconfiguration. Meanwhile, compounds 2 and 3 have good neuroprotective activity and cholinesterase inhibitory activity and are worthy of further development.

[0027]

[0028] BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 HRESIMS of compound 1, 1 H. 13 C-NMR and HMBC spectra;

[0030] Figure 2 HRESIMS of compound 2, 1 H. 13 C-NMR and HMBC spectra;

[0031] Figure 3 HRESIMS of compound 3, 1 H. 13 C-NMR and HMBC spectra;

[0032] Figure 4 HRESIMS of compound 4, 1 H. 13 C-NMR and HMBC spectra;

[0033] Figure 5 HRESIMS of compound 5, 1 H. 13 C-NMR and HMBC spectra;

[0034] Figure 6 HRESIMS of compound 6, 1 H. 13 C-NMR and HMBC spectra;

[0035] Figure 7 X single crystal data of compound 6;

[0036] Figure 8 Compounds 1-6 1 H- 1 H COSY and HMBC are related;

[0037] Fig. 9 Measured and calculated results of 3a-3d of compound 3 13 C NMR chemical shift linear correlation spectrum;

[0038] Fig.10 Measured and calculated ECD spectra of compounds 1-6;

[0039] Fig.11 Compounds 2 (a) and 3 (b) inhibited the activity of acetylcholinesterase in a dose-dependent manner (positive drug: donepezil; IC 50 =0.190±0.047 μM);

[0040] Fig.12 Compounds 2 (a) and 3 (b) inhibited the activity of butyrylcholinesterase in a dose-dependent manner (positive drug: donepezil; IC 50 =3.553±0.091μM);

[0041] Fig.13 Neuroprotective activity of Compound 2 and Compound 3. DETAILED DESCRIPTION

[0042] The following examples are intended to help those skilled in the art to better understand the present invention, but are not intended to limit the present invention in any way.

[0043] Example 1

[0044] Preparation of compound 1-6:

[0045] The whole plant of dried Daphne odora was extracted with ethanol, and the extracts were combined and concentrated to obtain an extract. The extract was extracted with ethyl acetate and the obtained components were subjected to silica gel column chromatography and gradient eluted with a dichloromethanol system of 1:0-0:1 to collect 10 components Fr.AJ;

[0046] The component Fr.C was depigmented by HP20 column chromatography using an ethanol-water system of 20:80-100:0.

[0047] The component Fr.C was gradient eluted using an ethanol-water system of 20:80-100:0 using ODS column chromatography to obtain 12 components Fr.C1-Fr.C12;

[0048] Compound 1-6 was obtained by silica gel column chromatography with a petroleum ether-ethyl acetate system of 100:1-1:1 as eluent and preparative reverse phase HPLC using a mobile phase of 70:30-30:70 acetonitrile-water to separate Fr.C5, Fr.C6 and Fr.C7.

[0049] Example 2

[0050] Study on the acetylcholinesterase inhibitory activity of compounds 1-6:

[0051] The compound was dissolved in DMSO and diluted to 5 series of concentrations with potassium phosphate buffer (KH2PO4 / K2HPO4, 0.1M, pH 7.4). The reaction system contained 25μl of the compound to be tested, 12.5μL of enzyme, 125μL of DTNB, and 50μL of ATCI. The reaction started after the addition of the enzyme. The absorbance was measured 3 times within 10 minutes after the addition of the enzyme at a wavelength of 412nm. The response concentration (logarithmic) curve was analyzed by nonlinear regression using the Graph-Pad Prism program to calculate the IC 50 The experimental results are as follows Fig.11 shown.

[0052] Example 3

[0053] Investigation of butyrylcholinesterase inhibitory activity of compounds 1-6:

[0054] The compound was dissolved in DMSO and diluted to 5 series of concentrations with potassium phosphate buffer (KH2PO4 / K2HPO4, 0.1M, pH 7.4). The reaction system contained 25μl of the compound to be tested, 10μL of enzyme, 125μL of DTNB, and 50μL of BTCI. The reaction started after the addition of the enzyme. The absorbance was measured 3 times within 10 minutes after the addition of the enzyme at a wavelength of 412nm. The response concentration (logarithmic) curve was analyzed by nonlinear regression using the Graph-Pad Prism program to calculate the IC 50 The experimental results are as follows Fig.12 shown.

[0055] Example 4

[0056] Neuroprotective activity of compounds 1-6:

[0057] Primary rat cortical neuron cells were placed in DMEM medium containing 10% FBS and cultured under the conditions of 100 μg / ml streptomycin and 100 U / ml penicillin. When the cell confluence reached 60%-80%, primary rat cortical neuron cells were seeded in 96-well plates at a seeding density of 1×10 6 / ml, 100μl per well, and culture at 37℃, 5% CO2.

[0058] Primary rat cortical neurons were divided into three groups: control group, glucose-oxygen deprivation / reoxygenation (OGD / R), and glucose-oxygen deprivation / reoxygenation + treatment. The in vitro ischemia model (OGD) was established by placing primary rat cortical neurons in sugar-free DMEM medium and then culturing them in a three-gas incubator filled with 94% N2, 5% CO2, and 1% O2. Afterwards, the OGD model cells were re-placed in complete medium and re-cultured for 24 hours to establish the OGD / R model.

[0059] The cell viability was detected by CCK8 colorimetry. 10 μl CCK8 was added to each well of the treatment group and incubated at 37°C for 1 hour; cells in the control group did not need to be treated. The absorbance was measured at 450 nm using an ELISA reader. Cell viability (%) = (OD value of the treatment group - OD value of the control group) / (OD value of the OGD / R group - OD value of the control group). The experimental results are shown in Fig.13 shown.

[0060] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A guaiacyl sesquiterpene derivative from Daphne odora, characterized in that: It is any of the following structures:

2. The guaiacane sesquiterpene derivative in Daphne odora according to claim 1, characterized in that: The orange flower daphne is a plant of the genus Daphne in the family Thymelaeaceae.

3. A method for preparing the guaiacane sesquiterpene derivatives from Daphne odora according to claim 1 or 2, characterized in that: The steps include: The whole plant of dried Daphne odora was extracted with ethanol, and the extracts were combined and concentrated to obtain an extract. The extract was extracted with ethyl acetate and the obtained components were subjected to silica gel column chromatography and gradient eluted with a dichloromethanol system of 1:0-0:1 to obtain 10 components Fr.AJ; The component Fr.C was gradient eluted using an ethanol-water system of 20:80-100:0 using HP20, ODS column chromatography to obtain 12 components Fr.C1-Fr.C12; Compound 1-3 was obtained by silica gel column chromatography with a petroleum ether-ethyl acetate system of 100:1-1:1 as eluent and by preparative reverse phase high performance liquid chromatography using an acetonitrile-water mobile phase to separate Fr.C5, Fr.C6 and Fr.C7.

4. The method for preparing the guaiacane sesquiterpene derivatives from Daphne odora according to claim 3, characterized in that: The orange flower daphne used is the orange flower daphne [Daphne aurantiaca] of the genus Daphne of the family Thymelaeaceae.

5. The method for preparing the guaiacane sesquiterpene derivatives from Daphne odora according to claim 3, characterized in that: The dried whole plant of Daphne koreana was extracted with 80% industrial ethanol for 3 times under reflux, each time for 2-3 hours.

6. The method for preparing the guaiacane sesquiterpene derivatives from Daphne odora according to claim 3, characterized in that: Fr.C5, Fr.C6 and Fr.C7 were separated using 70:30-30:70 acetonitrile-water mobile phase.

7. A pharmaceutical composition, characterized in that The invention comprises the guaiacane sesquiterpene derivative in Daphne odora as claimed in claim 1 or 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

8. Use of the guaiacane sesquiterpene derivative from Daphne odora as claimed in claim 1 or 2 or a pharmaceutically acceptable salt thereof in the preparation of a drug having neuroprotective activity and cholinesterase inhibitory activity.

9. Use of the pharmaceutical composition according to claim 7 in the preparation of drugs having neuroprotective activity and cholinesterase inhibitory activity.

10. Use of the guaiacane sesquiterpene derivative from Daphne koreana as claimed in claim 1 or 2 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in claim 7, in the preparation of a drug for preventing or treating Alzheimer's disease.